Oleclumab
- Generic Name
- Oleclumab
- Drug Type
- Biotech
- CAS Number
- 1803176-05-7
- Unique Ingredient Identifier
- 5CRY01URYQ
- Background
Oleclumab is under investigation in clinical trial NCT03819465 (A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC).
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
Phase 1
Active, not recruiting
- Conditions
- Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 175
- Registration Number
- NCT03819465
- Locations
- 🇹🇭
Research Site, Hat Yai, Thailand
Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial
Phase 1
Active, not recruiting
- Conditions
- Locally Advanced Lung Non-Small Cell CarcinomaLocally Recurrent Lung Non-Small Cell CarcinomaUnresectable Lung Non-Small Cell CarcinomaStage II Lung Cancer AJCC v8Stage III Lung Cancer AJCC v8
- Interventions
- Radiation: Accelerated Hypofractionated Radiation TherapyProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance Imaging of the Brain with and without ContrastRadiation: Radiation Therapy
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 26
- Registration Number
- NCT03801902
- Locations
- 🇺🇸
MD Anderson in The Woodlands, Conroe, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸MD Anderson West Houston, Houston, Texas, United States
A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
Phase 1
Completed
- Conditions
- Muscle Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2018-12-12
- Last Posted Date
- 2022-09-13
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT03773666
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
Phase 1
Active, not recruiting
- Conditions
- Triple Negative Breast Neoplasms
- Interventions
- First Posted Date
- 2018-11-15
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 243
- Registration Number
- NCT03742102
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC
Phase 1
Active, not recruiting
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2018-08-06
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 129
- Registration Number
- NCT03616886
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇫🇷CHU Poitiers, Poitiers, France
🇫🇷Hôpitaux Universitaires de Strasbourg, Strasbourg, France
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
Phase 1
Completed
- Conditions
- CarcinomaMetastatic Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 213
- Registration Number
- NCT03611556
- Locations
- 🇪🇸
Research Site, Pamplona, Spain
Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study
Phase 1
Active, not recruiting
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2017-12-21
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 43
- Registration Number
- NCT03381274
- Locations
- 🇨🇳
Research Site, Taichung, Taiwan
Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
Phase 2
Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: AZD6738 (ceralasertib)Drug: AZD6738 (ceralasertib) 7 days monotherapyDrug: AZD6738 (ceralasertib) (240 mg or 160 mg)
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 527
- Registration Number
- NCT03334617
- Locations
- 🇪🇸
Research Site, Sevilla, Spain
A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
Phase 1
Completed
- Conditions
- Advanced Solid MalignanciesNon-Small Cell Lung Cancer (NSCLC)Colorectal Carcinoma (CRC)Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)
- Interventions
- First Posted Date
- 2016-04-18
- Last Posted Date
- 2023-05-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 313
- Registration Number
- NCT02740985
- Locations
- 🇺🇸
Research Site, Nashville, Tennessee, United States
MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 192
- Registration Number
- NCT02503774
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath